| John L Foggle, MD | |
|
593 Eddy St, Claverick 2, Providence, RI 02903-4923 | |
| (401) 854-2504 | |
| (401) 854-2519 |
| Full Name | John L Foggle |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 35 Years |
| Location | 593 Eddy St, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720027253 | NPI | - | NPPES |
| 939025129 | Other | RI | RI MEDICARE GROUP NUMBER |
| NPI | Other | RI | 1720027253 |
| 12/29/2008 | Other | MA | TUFTS HEALTH PLAN |
| 9/26/2006 | Other | RI | NHPRI |
| 2119871 | Medicaid | MA | |
| 413496 | Other | RI | BCBSRI |
| 7058592 | Medicaid | RI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD12121 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Sinai Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fpa Hospital Based | 4789826694 | 479 |
News Archive
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
› Verified 3 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477899078 PECOS PAC ID: 2264691070 Enrollment ID: O20130717000798 |
News Archive
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
› Verified 3 days ago
| Entity Name | Fpa Hospital Based |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629319413 PECOS PAC ID: 4789826694 Enrollment ID: O20130806000185 |
News Archive
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
› Verified 3 days ago
| Entity Name | Icahn School Of Medicine At Mount Sinai |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679083984 PECOS PAC ID: 6103251491 Enrollment ID: O20200114002920 |
News Archive
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John L Foggle, MD Po Box 9484, Providence, RI 02940-9484 Ph: (401) 854-2500 | John L Foggle, MD 593 Eddy St, Claverick 2, Providence, RI 02903-4923 Ph: (401) 854-2504 |
News Archive
Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.
S*BIO Pte Ltd today announced that the European Commission (EC) has granted orphan drug designation to SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF). SB1518 has also received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of the same disorder.
A drug with potential to prevent epilepsy caused by a genetic condition may also help prevent more common forms of epilepsy caused by brain injury, according to researchers at Washington University School of Medicine in St. Louis.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
› Verified 3 days ago
Dr. Robert A Partridge, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St, Claverick 2, Providence, RI 02903 Phone: 401-519-1604 Fax: 401-272-0538 | |
Dr. Gregory R Lockhart, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Claverick 2, Providence, RI 02903 Phone: 401-444-4000 Fax: 401-427-7795 | |
Ian M Jacobson, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 825 Chalkstone Ave, Providence, RI 02908 Phone: 330-493-4443 | |
Dr. Daniel Shanin, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 593 Eddy St., Claverick 2, Providence, RI 02903 Phone: 401-444-4000 | |
Carli Renske Reisdorf, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-6680 | |
Dr. Oriane Diana Longerstaey, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 164 Summit Ave, Providence, RI 02906 Phone: 704-355-3181 | |
Rachel Smith Shain, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 593 Eddy St, Providence, RI 02903 Phone: 401-444-6489 Fax: 401-444-6662 |